BREAST CANCER

A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.

Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2021 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer.

Experts in breast cancer review the case of a 42-year-old woman with grade 2, node-positive invasive ductal carcinoma and discuss updated data from the RxPONDER trial on adjuvant chemotherapy benefit in premenopausal women.

Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.

Kevin Kalinsky, MD, MS, discussed selective estrogen receptor downregulators being explored for the treatment of breast cancer clinical trials.

Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.

In the phase 3 monarchE clinical trial, long-term follow-up results show that the benefit of abemaciclib plus endocrine therapy continued beyond 2 years.

A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.

Results from 3 clinical trials show that adjuvant CDK4/6 inhibition is a good option for early-stage hormone-receptor-positive breast cancer.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.

According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.

Sunil Badve, MD, FRCPath, and Heather McArthur, MD, evaluate best practices around Ki67 assessment when approaching treatment for HR+ early breast cancer.

Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.

Experts in breast cancer review the case of a 54-year-old postmenopausal woman with stage IIB, high-risk, HR+ early-stage breast cancer and discuss factors to consider when assessing risk for systemic occurrence.

Guidance on how to treat a 67-year-old patient with ER-positive/PR-positive breast cancer, and additional therapies in the pipeline that have the potential to improve treatment.

An overview of CDK4/6 inhibitors available for patients with advanced or metastatic HR-positive breast cancer, and recommendations for managing common adverse events associated with therapy.

The rationale for treating patients with early-stage HR-positive breast cancer with abemaciclib and endocrine therapy.

Kevin Kalinsky, MD, MS, presents a case of ER-positive/PR-positive breast cancer and highlights the prevalence of cases such as this in the United States.

Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.

In an interview with Targeted Oncology, Lee Schwartzberg, MD, further discusses the findings of KEYNOTE-522 and pembrolizumab in patients with triple negative breast cancer.

In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.

During a live virtual event, Sara Tolaney, MD, discussed the results of the ASCENT trial of sacituzumab govitecan in patients with triple-negative breast cancer.

Lowell Hart, MD, FACP, discusses what he’d like to see in the future for the treatment of ER+ breast cancer and includes a note concerning Ki-67 analyses.

Dr Hart explains his prognosis for our case patient.

Lowell Hart, MD, FACP, lists the different types of adverse events that are common when CDK4/6 inhibitors are used in both the adjuvant and advanced cancer setting.

In its new Sunnyvale, Texas location, GenesisCare offers comprehensive patient-centered services for patients with breast cancer.